News Pfizer's Arena buyout looks canny, as etrasimod aces phase 3... Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceu
News Flush with COVID cash, Pfizer tables $6.7bn bid for Arena Pfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing to buy Arena Pharma and its late-stage ulcerative colitis drug etras
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.